Targeted lapatinib anti-HER2/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem

Abstract

Approximately 20% of invasive breast cancers have upregulation/gene amplification of the oncogene human epidermal growth factor receptor-2 (HER2/ErbB2). Of these, some also express steroid receptors (the so-called Luminal B subtype), whereas others do not (the HER2 subtype). HER2 abnormal breast cancers are associated with a worse prognosis, chemotherapy resistance, and sensitivity to selected anti-HER2 targeted therapeutics. Transcriptional data from over 3000 invasive breast cancers suggest that this approach is overly simplistic; rather, the upregulation of HER2 expression resulting from gene amplification is a driver event that causes major transcriptional changes involving numerous genes and pathways in breast cancer cells. Most notably, this includes a shift from estrogenic dependence to regulatory controls driven by other nuclear receptors, particularly the androgen receptor. We discuss members of the HER receptor tyrosine kinase family, heterodimer formation, and downstream signaling, with a focus on HER2 associated pathology in breast carcinogenesis. The development and application of anti-HER2 drugs, including selected clinical trials, are discussed. In light of the many excellent reviews in the clinical literature, our emphasis is on recently developed and successful strategies to overcome targeted therapy resistance. These include combining anti-HER2 agents with programmed cell death-1 ligand or cyclin-dependent kinase 4/6 inhibitors, targeting crosstalk between HER2 and other nuclear receptors, lipid/cholesterol synthesis to inhibit receptor tyrosine kinase activation, and metformin, a broadly inhibitory drug. We seek to facilitate a better understanding of new approaches to overcome anti-HER2 drug resistance and encourage exploration of two other therapeutic interventions that may be clinically useful for HER+ invasive breast cancer patients.

Keywords

HER2/ErbB2 / receptor tyrosine kinase / tyrosine kinase resistance / nuclear receptor / androgen receptor / lipid metabolism / programmed cell death-1 ligand / CDK 4/6 inhibitor

References

[1] Burstein HJ.The distinctive nature of HER2-positive breast cancers..N Engl J Med2005;353:1652-4

[2] Slamon DJ,Wong SG,Ullrich A.Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene..Science1987;235:177-82

[3] Kennecke H,Woods R,Voduc D.Metastatic behavior of breast cancer subtypes..J Clin Oncol2010;28:3271-7

[4] Slamon DJ,Jones LA,Wong SG.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer..Science1989;244:707-12

[5] Arteaga CL.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics..Cancer Cell2014;25:282-303 PMCID:PMC4018830

[6] Brennan PJ,Berezov A,Greene MI.HER2/neu: mechanisms of dimerization/oligomerization..Oncogene2000;19:6093-101

[7] Brown-Glaberman U,Royce M.HER2-targeted therapy for early-stage breast cancer: a comprehensive review..Oncology (Williston Park)2014;28:281-9

[8] Carey LA.Breast cancer: HER2--a good addiction..Nat Rev Clin Oncol2012;9:196-7 PMCID:PMC6699174

[9] Loibl S.HER2-positive breast cancer..Lancet2017;389:2415-29

[10] Nahta R,Hung MC,Esteva FJ.Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer..Nat Clin Pract Oncol2006;3:269-80

[11] Slamon D,Robert N,Martin M.Adjuvant trastuzumab in HER2-positive breast cancer..N Engl J Med2011;365:1273-83 PMCID:PMC3268553

[12] Suh KJ,Kim JW,Lee HS.EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release..Oncotarget2017;8:63901-10 PMCID:PMC5609971

[13] Giordano SH,Chandarlapaty S,Esteva FJ.Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update..J Clin Oncol2018;36:2736-40

[14] Wolff AC,Allison KH,Mangu PB.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update..Arch Pathol Lab Med2018;142:1364-82

[15] Wolff AC,Allison KH,Mangu PB.Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update..J Clin Oncol2018;36:2105-22

[16] Daemen A.HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumors..Breast Cancer Res2018;20:8 PMCID:PMC5791377

[17] Lee HJ,Park SY,Song IH.Clinicopathologic significance of the intratumoral heterogeneity of HER2 gene amplification in HER2-positive breast cancer patients treated with adjuvant trastuzumab..Am J Clin Pathol2015;144:570-8

[18] Muss HB,Berry DA,Liu ET.c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer..N Engl J Med1994;330:1260-6

[19] Paik S,Tan-Chiu E,Park C.HER2 and choice of adjuvant chemotherapy for invasive breast cancer: national surgical adjuvant breast and bowel project protocol B-15..J Natl Cancer Inst2000;92:1991-8

[20] Yates LR,Wedge D,Gonzalez S.Genomic evolution of breast cancer metastasis and relapse..Cancer Cell2017;32:169-84.e7 PMCID:PMC5559645

[21] Baselga J,Eidtmann H,de Azambuja E.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial..Lancet2012;379:633-40 PMCID:PMC5705192

[22] Perez EA,Suman VJ,Sledge G.Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831..J Clin Oncol2014;32:3744-52 PMCID:PMC4226805

[23] Wang J.Targeted therapeutic options and future perspectives for HER2-positive breast cancer..Signal Transduct Target Ther2019;4:34 PMCID:PMC6799843

[24] Fink MY.Survival of HER2-positive breast cancer cells: receptor signaling to apoptotic control centers..Genes Cancer2013;4:187-95 PMCID:PMC3782004

[25] Blackwell KL,Storniolo AM,Sledge G.Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer..J Clin Oncol2010;28:1124-30

[26] Blackwell KL,Storniolo AM,Sledge G.Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study..J Clin Oncol2012;30:2585-92

[27] Bonnefoi H,Saghatchian M,Venat-Bouvet L.Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study..Ann Oncol2015;26:325-32 PMCID:PMC4304382

[28] Milani A,Gioeni L,Valabrega G.Role of trastuzumab in the management of HER2-positive metastatic breast cancer..Breast Cancer (Dove Med Press)2010;2:93-109 PMCID:PMC3846373

[29] Burris HA3rd.Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib..Oncologist.2004;9 Suppl 3:10-5

[30] Richard S,Lotz JP,Gligorov J.Pertuzumab and trastuzumab: the rationale way to synergy..An Acad Bras Cienc.2016;88 Suppl 1:565-77

[31] Paranjpe R,Tao G,Noormohammed S.Neratinib in HER2-positive breast cancer patients..Ann Pharmacother2019;53:612-20

[32] Moulder SL,Baetz T,Fernetich G.Phase I study of ONT-380, a HER2 inhibitor, in patients with HER2(+)-advanced solid tumors, with an expansion cohort in HER2(+) metastatic breast cancer (MBC)..Clin Cancer Res2017;23:3529-36

[33] Murthy R,Conlin A,Chamberlain M.Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study..Lancet Oncol2018;19:880-8

[34] Rugo HS,Wright GLS,DeLaurentiis M.SOPHIA primary analysis: a phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)..J Clin Oncol2019;37:1000

[35] Bang YJ,Im SA,Bauer TM.First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors..Ann Oncol2017;28:855-61 PMCID:PMC6246722

[36] Berlato C,Price AM,Scibetta AG.Alternative TFAP2A isoforms have distinct activities in breast cancer..Breast Cancer Res2011;13:R23 PMCID:PMC3219183

[37] Kojima Y,Kawamoto H,Uejima T.Trastuzumab emtansine (T-DM1) plus S-1 in patients with trastuzumab-pretreated HER2-positive advanced or metastatic breast cancer: a phase Ib study..Oncology2019;96:309-17

[38] Peters S,Bubendorf L,Villegas A.Trastuzumab emtansine (T-DM1) in patients with previously treated HER2-overexpressing metastatic non-small cell lung cancer: efficacy, safety, and biomarkers..Clin Cancer Res2019;25:64-72

[39] Doi T,Naito Y,Fujiwara Y.Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study..Lancet Oncol2017;18:1512-22

[40] Loganzo F,Sung M,Myers JS.Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments..Mol Cancer Ther2015;14:952-63

[41] Blackwell KL,Tan-Chiu E,Arbushites MC.Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens..Ann Oncol2009;20:1026-31

[42] Cameron D,Oliva C,Imwalle B.Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial..Oncologist2010;15:924-34 PMCID:PMC3228041

[43] D’Amato V,Formisano L,De Placido S.Mechanisms of lapatinib resistance in HER2-driven breast cancer..Cancer Treat Rev2015;41:877-83

[44] de Azambuja E,Piccart-Gebhart M,Di Cosimo S.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response..Lancet Oncol2014;15:1137-46

[45] Eustace AJ,McDermott MSJ,O’Leary P.Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL..BMC Cancer2018;18:965 PMCID:PMC6180577

[46] Gelmon KA,Kaufman B,Manikhas A.Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA.31..J Clin Oncol2015;33:1574-83

[47] Geyer CE,Lindquist D,Romieu CG.Lapatinib plus capecitabine for HER2-positive advanced breast cancer..N Engl J Med2006;355:2733-43

[48] Guarneri V,Bottini A,Bisagni G.Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study..J Clin Oncol2012;30:1989-95

[49] Liu L,Shi H,Greshock J.Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL..Cancer Res2009;69:6871-8

[50] Nahta R,Du Y.Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling..Mol Cancer Ther2007;6:667-74

[51] Perry J,Kitromilidou C,Joel S.A synergistic interaction between lapatinib and chemotherapy agents in a panel of cell lines is due to the inhibition of the efflux pump BCRP..Mol Cancer Ther2010;9:3322-9

[52] Pernas S.HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance..Ther Adv Med Oncol2019;11:1758835919833519 PMCID:PMC6425535

[53] Spector NL.Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer..J Clin Oncol2009;27:5838-47

[54] Rimawi MF,Osborne CK.Targeting HER2 for the treatment of breast cancer..Annu Rev Med2015;66:111-28

[55] Serra V,Prudkin L,Ibrahim YH.PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer..Oncogene2011;30:2547-57 PMCID:PMC3107390

[56] Nahta R,Zhang B,Esteva FJ.Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells..Cancer Res2005;65:11118-28

[57] Minuti G,Duchnowska R,Fabi A.Increased MET and HGF gene copy numbers are associated with trastuzumab failure in HER2-positive metastatic breast cancer..Br J Cancer2012;107:793-9 PMCID:PMC3425981

[58] Nagata Y,Zhou X,Esteva FJ.PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients..Cancer Cell2004;6:117-27

[59] Berns K,Hennessy BT,Hijmans EM.A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer..Cancer Cell2007;12:395-402

[60] Scaltriti M,Ocana A,Guzman M.Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer..J Natl Cancer Inst2007;99:628-38

[61] Chandarlapaty S,Giri D,Heguy A.Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer..Clin Cancer Res2012;18:6784-91 PMCID:PMC3525734

[62] Giordano SH,Chandarlapaty S,Esteva FJ.Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO clinical practice guideline update..J Clin Oncol2018;36:2736-40

[63] Aird KM,Peplinski S,Devi GR.X-linked inhibitor of apoptosis protein inhibits apoptosis in inflammatory breast cancer cells with acquired resistance to an ErbB1/2 tyrosine kinase inhibitor..Mol Cancer Ther2010;9:1432-42 PMCID:PMC2957814

[64] Martin AP,Emad L,Walker T.Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation..Mol Pharmacol2008;74:807-22 PMCID:PMC2574656

[65] Goyette MA,Aubert L,Savage P.The receptor tyrosine kinase AXL is required at multiple steps of the metastatic cascade during HER2-positive breast cancer progression..Cell Rep2018;23:1476-90

[66] Hafizi S.Signalling and functional diversity within the Axl subfamily of receptor tyrosine kinases..Cytokine Growth Factor Rev2006;17:295-304

[67] Korshunov VA.Axl-dependent signalling: a clinical update..Clin Sci (Lond)2012;122:361-8 PMCID:PMC3609429

[68] Junttila TT,Parsons K,Lewis Phillips GD.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941..Cancer Cell2009;15:429-40

[69] Toomey S,Fay J,Carr A.Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies..Breast Cancer Res2017;19:87 PMCID:PMC5530949

[70] Nam HJ,Oh DY,Kim HP.Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer..Mol Cancer Ther2013;12:16-26

[71] Milani A,Montemurro F,Valabrega G.Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives..Ann Oncol2013;24:1740-8

[72] Ayoub NM,Yaghan RJ.Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches..Breast Cancer (Dove Med Press)2019;11:53-69 PMCID:PMC6340364

[73] Shah AN,Rademaker A,Jain S.A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC)..J Clin Oncol2019;37:1096

[74] Chaganty BKR,Gest A,Ivan C.Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFNgamma secretion..Cancer Lett2018;430:47-56 PMCID:PMC6004098

[75] Griguolo G,Dieci MV,Prat A.Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer..J Immunother Cancer2019;7:90 PMCID:PMC6439986

[76] Wargo JA,Cooper ZA,Sullivan RJ.Immune effects of chemotherapy, radiation, and targeted therapy and opportunities for combination with immunotherapy..Semin Oncol2015;42:601-16 PMCID:PMC4955940

[77] Ryu EB,Seo M,Lim JH.Tumour volume doubling time of molecular breast cancer subtypes assessed by serial breast ultrasound..Eur Radiol2014;24:2227-35

[78] Matutino A,Verma S.CDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease..Ther Adv Med Oncol2018;10:1758835918818346 PMCID:PMC6299331

[79] Sobhani N,Pittacolo M,Miccoli A.Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer..Cells2019;8: PMCID:PMC6523967

[80] Pernas S,Winer EP.CDK4/6 inhibition in breast cancer: current practice and future directions..Ther Adv Med Oncol2018;10:1758835918786451 PMCID:PMC6050811

[81] Knudsen ES.The strange case of CDK4/6 inhibitors: mechanisms, resistance, and combination strategies..Trends Cancer2017;3:39-55 PMCID:PMC5347397

[82] Preusser M,Thill M,Bartsch R.CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion..ESMO Open2018;3:e000368 PMCID:PMC6109817

[83] Zhang K,Kaping L,Xia W.CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer..Cancer Lett2019;447:130-40

[84] Goel S,Watt AC,Dillon DA.Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors..Cancer Cell2016;29:255-69 PMCID:PMC4794996

[85] Cordera F.Steroid receptors and their role in the biology and control of breast cancer growth..Semin Oncol2006;33:631-41

[86] Mehta A.Co-targeting estrogen receptor and HER2 pathways in breast cancer..Breast2014;23:2-9

[87] Grogg A,Pfaltz K,Droeser RA.Androgen receptor status is highly conserved during tumor progression of breast cancer..BMC Cancer2015;15:872 PMCID:PMC4640208

[88] Park S,Park HS,Choi SY.Expression of androgen receptors in primary breast cancer..Ann Oncol2010;21:488-92

[89] Barton VN,Gordon MA,Spoelstra NS.Multiple molecular subtypes of triple-negative breast cancer critically rely on androgen receptor and respond to enzalutamide in vivo..Mol Cancer Ther2015;14:769-78 PMCID:PMC4534304

[90] D’Amato NC,Babbs B,Carson Butterfield KT.Cooperative dynamics of AR and ER activity in breast cancer..Mol Cancer Res2016;14:1054-67 PMCID:PMC5107172

[91] Krishnan AV,Feldman D.Vitamin D and breast cancer: inhibition of estrogen synthesis and signaling..J Steroid Biochem Mol Biol2010;121:343-8

[92] Mehta S,Bosch RJ,Urassa W.Vitamin D status and TB treatment outcomes in adult patients in Tanzania: a cohort study..BMJ Open2013;3:e003703 PMCID:PMC3840339

[93] Abduljabbar R,Lai CF,Al-Kaabi M.Clinical and biological significance of glucocorticoid receptor (GR) expression in breast cancer..Breast Cancer Res Treat2015;150:335-46

[94] Vilasco M,Mourra N,Forgez P.Glucocorticoid receptor and breast cancer..Breast Cancer Res Treat2011;130:1-10

[95] Hua S,White KP.Genomic antagonism between retinoic acid and estrogen signaling in breast cancer..Cell2009;137:1259-71 PMCID:PMC3374131

[96] Ross-Innes CS,Holmes KA,Spyrou C.Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer..Genes Dev2010;24:171-82 PMCID:PMC2807352

[97] Gao S,Gerrin S,Sharma A.ErbB2 signaling increases androgen receptor expression in abiraterone-resistant prostate cancer..Clin Cancer Res2016;22:3672-82 PMCID:PMC4947432

[98] Browne BC,Venkatesan N,Clynes M.Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells..Ann Oncol2011;22:68-73

[99] Gordon MA,Gu H,Wulfkuhle J.Synergy between androgen receptor antagonism and inhibition of mTOR and HER2 in breast cancer..Mol Cancer Ther2017;16:1389-400 PMCID:PMC5517319

[100] Micello D,Sahnane N,Capella C.Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers..Virchows Arch2010;457:467-76

[101] He L,Xiong X,Zhu Z.Targeting androgen receptor in treating HER2 positive breast cancer..Sci Rep2017;7:14584 PMCID:PMC5674043

[102] Trudeau ME,Steinberg JL,Poondru S.A phase 2 single-arm study to assess clinical activity, efficacy and safety of enzalutamide (ENZA) with trastuzumab in HER2+ AR+ metastatic or locally advanced breast cancer..J Clin Oncol2015;33:tps640

[103] Lee-Bitar JS,Yost SE,Martinez N.A phase II clinical trial of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor-positive triple-negative breast cancer..J Clin Oncol2019;37:1069

[104] Carter PR,Chandran S,Potluri R.3106 Patients with a diagnosis of hyperlipidaemia have a reduced risk of developing breast cancer and lower mortality rates: a large retrospective longitudinal cohort study from the UK ACALM registry..Eur Heart J2017;38:

[105] Ikonen E.Roles of lipid rafts in membrane transport..Curr Opin Cell Biol2001;13:470-7

[106] Sezgin E,Mayor S.The mystery of membrane organization: composition, regulation and roles of lipid rafts..Nat Rev Mol Cell Biol2017;18:361-74 PMCID:PMC5500228

[107] Chen X.Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor..J Biol Chem2002;277:49631-7

[108] Borgquist S,Kimbung S.Statins: a role in breast cancer therapy?.J Intern Med2018;284:346-57 PMCID:PMC6175478

[109] Gobel A,Rauner M,Rachner TD.Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells..Cell Death Dis2019;10:91 PMCID:PMC6349912

[110] Zhao Z,Pan Y,Zhao T.Simvastatin downregulates HER2 via upregulation of PEA3 to induce cell death in HER2-positive breast cancer cells..Oncol Res2012;20:187-95

[111] Adam RM,Kim J,Cinar B.Cholesterol sensitivity of endogenous and myristoylated Akt..Cancer Res2007;67:6238-46

[112] Elmore S.Apoptosis: a review of programmed cell death..Toxicol Pathol2007;35:495-516 PMCID:PMC2117903

[113] Gao X.Spatiotemporal analysis of differential Akt regulation in plasma membrane microdomains..Mol Biol Cell2008;19:4366-73 PMCID:PMC2555921

[114] Wahdan-Alaswad RS,Salem HS.Metformin targets cholesterol biosynthesis pathway,GM1 lipid raft stabilization, EGFR signaling and proliferation in triple negative breast cancers..Cancer Therapy Oncol Int J2018;9:555765

[115] Cufi S,Vazquez-Martin A,Dorca J.Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts..Oncotarget2012;3:395-8 PMCID:PMC3380574

[116] Wahdan-Alaswad R,Edgerton SM,Deng XS.Glucose promotes breast cancer aggression and reduces metformin efficacy..Cell Cycle2013;12:3759-69 PMCID:PMC3905068

[117] Wahdan-Alaswad RS,Salem HS.Metformin targets glucose metabolism in triple negative breast cancer..J Oncol Transl Res2018;4: PMCID:PMC5959056

[118] McIlhinney RA.Membrane targeting via protein N-myristoylation..Methods Mol Biol1998;88:211-25

[119] Sethunath V,De Angelis C,Qin L.Targeting the mevalonate pathway to overcome acquired anti-HER2 treatment resistance in breast cancer..Mol Cancer Res2019;17:2318-30 PMCID:PMC6825570

[120] Brown DN,Cirmena G,Garuti A.Squalene epoxidase is a bona fide oncogene by amplification with clinical relevance in breast cancer..Sci Rep2016;6:19435 PMCID:PMC4726025

[121] Alimova IN,Fan Z,Dillon T.Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro..Cell Cycle2009;8:909-15

[122] Liu B,Edgerton SM,Alimova IN.Metformin induces unique biological and molecular responses in triple negative breast cancer cells..Cell Cycle2009;8:2031-40

[123] Liu B,Edgerton SM,Lind SE.Potent anti-proliferative effects of metformin on trastuzumab-resistant breast cancer cells via inhibition of erbB2/IGF-1 receptor interactions..Cell Cycle2011;10:2959-66

[124] Kim HJ,Lee JW,Lee SB.Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes..Breast Cancer Res2015;17:64 PMCID:PMC4504447

[125] Sonnenblick A,Bradbury I,Azim Jr HA.Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2-positive primary breast cancer: analysis from the ALTTO phase III randomized trial..J Clin Oncol2017;35:1421-9 PMCID:PMC5455460

[126] Martin-Castillo B,Dorca J,Martinez S.A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study..Oncotarget2018;9:35687-704 PMCID:PMC6235018

[127] Berstein LM.New developments of metformin in the clinical cancer area..Oncotarget2018;9:36820-1 PMCID:PMC6305146

[128] McCullough AE,Reinholz MM,Dueck AC.Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study..Breast Cancer Res Treat2014;143:485-92 PMCID:PMC4039190

[129] Piccart-Gebhart M,Baselga J,Dueck AC.Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: results from the randomized phase iii adjuvant lapatinib and/or trastuzumab treatment optimization trial..J Clin Oncol2016;34:1034-42 PMCID:PMC4872016

[130] Holmes EM,Williams LS,de Azambuja E.Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial..Ann Oncol2019;30:1507-13 PMCID:PMC6931237

[131] Carey LA,Cirrincione CT,Pitcher BN.Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a Randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib..J Clin Oncol2016;34:542-9 PMCID:PMC4980567

[132] Goss PE,O’Shaughnessy J,Kaufmann M.Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial..Lancet Oncol2013;14:88-96

[133] Robidoux A,Rastogi P,Azar CA.Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial..Lancet Oncol2013;14:1183-92

[134] Hurvitz S,Adams B,Chan D.Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)..Ther Adv Med Oncol2018;10:1758835918807339 PMCID:PMC6236634

[135] Untch M,Bischoff J,Kaufmann M.Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial..Lancet Oncol2012;13:135-44

[136] Trowe T,Calkins K,Fong R.EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation..Clin Cancer Res2008;14:2465-75

[137] Xia W,Zhao S,Osada T.An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models..Breast Cancer Res2013;15:R85 PMCID:PMC3978995

[138] Rexer BN,Rinehart C,Granja-Ingram Nde M.Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition..Oncogene2011;30:4163-74 PMCID:PMC3204390

[139] Formisano L,Rosa R,D’Amato C.Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models..Breast Cancer Res2014;16:R45 PMCID:PMC4076622

[140] Eichhorn PJ,Scaltriti M,Guzman M.Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235..Cancer Res2008;68:9221-30 PMCID:PMC2587064

[141] Brady SW,Tsai MH.PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition..Cancer Biol Ther2015;16:402-11 PMCID:PMC4623386

[142] Vazquez-Martin A,Colomer R,Menendez JA.Low-scale phosphoproteome analyses identify the mTOR effector p70 S6 kinase 1 as a specific biomarker of the dual-HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb) in human breast carcinoma cells..Ann Oncol2008;19:1097-109

[143] Gayle SS,O’Regan RM.Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance..Anticancer Agents Med Chem2012;12:151-62 PMCID:PMC3288300

[144] Wurz GT,DeGregorio MW.Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential..Ther Adv Med Oncol2016;8:4-31 PMCID:PMC4699263

[145] Li BT,Buonocore D,Ni A.Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: results from a phase II basket trial..J Clin Oncol.2018;36:2532-7 PMCID:PMC6366814

[146] Loi S,Beavis PA,Denkert C.RAS/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1/PD-L1 immune checkpoint inhibitors..Clin Cancer Res2016;22:1499-509 PMCID:PMC4794351

[147] Loi S,Gombos A,Hui R.Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial..Lancet Oncol2019;20:371-82

[148] Giuliano M,Rognoni C,Jerusalem G.Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis..Lancet Oncol2019;20:1360-9

[149] Wang YC,Gillihan R,Ward RM.Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation..Breast Cancer Res2011;13:R121 PMCID:PMC3326563

[150] Gucalp A,Isakoff SJ,Liu MC.Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer..Clin Cancer Res2013;19:5505-12 PMCID:PMC4086643

[151] Giovannelli P,Galasso G.The androgen receptor in breast cancer..Front Endocrinol (Lausanne).2018;9:492 PMCID:PMC6122126